Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study
Abstract Background Evidence about safety and efficacy of transcatheter aortic valve replacement (TAVR) with the Venus A-Valve system (Venus Medtech, Hangzhou, China) remains limited for patients with pure native aortic regurgitation (PNAR). Objectives The single-center study sought to report the on...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-023-03329-1 |
| _version_ | 1827911019014389760 |
|---|---|
| author | Hua-Jie Zheng Yong-Bo Cheng Chao-Jun Yan De-Qing Lin San-Jiu Yu Jun Li Ping He Wei Cheng |
| author_facet | Hua-Jie Zheng Yong-Bo Cheng Chao-Jun Yan De-Qing Lin San-Jiu Yu Jun Li Ping He Wei Cheng |
| author_sort | Hua-Jie Zheng |
| collection | DOAJ |
| description | Abstract Background Evidence about safety and efficacy of transcatheter aortic valve replacement (TAVR) with the Venus A-Valve system (Venus Medtech, Hangzhou, China) remains limited for patients with pure native aortic regurgitation (PNAR). Objectives The single-center study sought to report the one-year clinical outcomes of the Venus A-Valve in the treatment of PNAR. Methods This study was a retrospective analysis of prospectively collected data. Data was from all consecutive patients who had PNAR and underwent TAVR with the Venus A-Valve system at our center from July 2020 and June 2021. Procedural and clinical outcomes up to one year were analyzed using Valve Academic Research Consortium-2 criteria. Results A total of 45 consecutive patients with PNAR underwent transfemoral TAVR with the Venus A-Valve system. The Mean age was 73.5 ± 5.5 years and 26.7% were female. All the TAVR procedures were performed via transfemoral access. Implantations were successful in 44 cases (97.8%). Only one patient was converted to surgical aortic valve replacement. No patient died intraoperatively. No second valve was implanted. In-hospital mortality rate was 2.3%. The one-year all-cause mortality rate was 4.7% without cardiovascular related death. No patient had moderate or severe paravalvular leakage during follow-up. At one year, the mean pressure gradient was 8.8 ± 0.9 mmHg, and left ventricular ejection fraction increased to 61.5 ± 3.6%. Conclusions This single-center study demonstrated the safety and efficacy of transfemoral TAVR with the Venus A-Valve in the treatment of patients with PNAR. |
| first_indexed | 2024-03-13T01:57:27Z |
| format | Article |
| id | doaj.art-728bbd8e82d04017900f732161d3a537 |
| institution | Directory Open Access Journal |
| issn | 1471-2261 |
| language | English |
| last_indexed | 2024-03-13T01:57:27Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj.art-728bbd8e82d04017900f732161d3a5372023-07-02T11:06:41ZengBMCBMC Cardiovascular Disorders1471-22612023-06-012311910.1186/s12872-023-03329-1Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center studyHua-Jie Zheng0Yong-Bo Cheng1Chao-Jun Yan2De-Qing Lin3San-Jiu Yu4Jun Li5Ping He6Wei Cheng7Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Department of Cardiac Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)Abstract Background Evidence about safety and efficacy of transcatheter aortic valve replacement (TAVR) with the Venus A-Valve system (Venus Medtech, Hangzhou, China) remains limited for patients with pure native aortic regurgitation (PNAR). Objectives The single-center study sought to report the one-year clinical outcomes of the Venus A-Valve in the treatment of PNAR. Methods This study was a retrospective analysis of prospectively collected data. Data was from all consecutive patients who had PNAR and underwent TAVR with the Venus A-Valve system at our center from July 2020 and June 2021. Procedural and clinical outcomes up to one year were analyzed using Valve Academic Research Consortium-2 criteria. Results A total of 45 consecutive patients with PNAR underwent transfemoral TAVR with the Venus A-Valve system. The Mean age was 73.5 ± 5.5 years and 26.7% were female. All the TAVR procedures were performed via transfemoral access. Implantations were successful in 44 cases (97.8%). Only one patient was converted to surgical aortic valve replacement. No patient died intraoperatively. No second valve was implanted. In-hospital mortality rate was 2.3%. The one-year all-cause mortality rate was 4.7% without cardiovascular related death. No patient had moderate or severe paravalvular leakage during follow-up. At one year, the mean pressure gradient was 8.8 ± 0.9 mmHg, and left ventricular ejection fraction increased to 61.5 ± 3.6%. Conclusions This single-center study demonstrated the safety and efficacy of transfemoral TAVR with the Venus A-Valve in the treatment of patients with PNAR.https://doi.org/10.1186/s12872-023-03329-1Transcatheter aortic valve replacementPure native aortic regurgitationVenus A-ValveClinical outcomes |
| spellingShingle | Hua-Jie Zheng Yong-Bo Cheng Chao-Jun Yan De-Qing Lin San-Jiu Yu Jun Li Ping He Wei Cheng Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study BMC Cardiovascular Disorders Transcatheter aortic valve replacement Pure native aortic regurgitation Venus A-Valve Clinical outcomes |
| title | Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study |
| title_full | Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study |
| title_fullStr | Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study |
| title_full_unstemmed | Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study |
| title_short | Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study |
| title_sort | transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation one year outcomes of a single center study |
| topic | Transcatheter aortic valve replacement Pure native aortic regurgitation Venus A-Valve Clinical outcomes |
| url | https://doi.org/10.1186/s12872-023-03329-1 |
| work_keys_str_mv | AT huajiezheng transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT yongbocheng transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT chaojunyan transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT deqinglin transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT sanjiuyu transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT junli transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT pinghe transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy AT weicheng transfemoraltranscatheteraorticvalvereplacementforpurenativeaorticregurgitationoneyearoutcomesofasinglecenterstudy |